velpatasvir (BioDeep_00000821285)
代谢物信息卡片
velpatasvir
化学式: C49H54N8O8 (882.4064404000001)
中文名称: 维帕他韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
InChI: InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
描述信息
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:133009
- KEGGdrug: D10806
- PubChem: 67683363
- DrugBank: DB11613
- ChEMBL: CHEMBL3545062
- CAS: 1377049-84-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sadaf Yasmeen, Aslam Khan, Fareeha Anwar, Muhammad Furqan Akhtar, Sidra Yasmeen, Shafeeq Ali Shah. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats.
Environmental science and pollution research international.
2023 Aug; ?(?):. doi:
10.1007/s11356-023-29134-z. [PMID: 37556059] - Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2022 Nov; 121(11):2265-2272. doi:
10.1016/j.jfma.2022.04.020. [PMID: 35581112] - Fredrick Kateera, Fabienne Shumbusho, Linda Manirambona, Jules Kabihizi, Anthere Murangwa, Janvier Serumondo, Jean Damascene Makuza, Sabin Nsanzimana, Claude Mambo Muvunyi, Jean Damascene Kabakambira, Habarurema Sylvain, Gregory Camus, Philip M Grant, Neil Gupta. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
The lancet. Gastroenterology & hepatology.
2022 06; 7(6):533-541. doi:
10.1016/s2468-1253(21)00398-8. [PMID: 35248213] - Vincenzo Messina, Riccardo Nevola, Antonio Izzi, Pellegrino De Lucia Sposito, Aldo Marrone, Roberto Rega, Raffaele Fusco, Paolina Lumino, Luca Rinaldi, Pasqualina Gaglione, Filomena Simeone, Ferdinando Carlo Sasso, Paolo Maggi, Luigi Elio Adinolfi. Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
Scientific reports.
2022 04; 12(1):5771. doi:
10.1038/s41598-022-09741-5. [PMID: 35388092] - Q Xu, W Zhang, Y X Ma, C N He, L T Zhang, Yilihamu Abulitifu, Y Li, N Wang, H L Wang, Y Y Zhao, X Gao, P G Gao, X Y Su, S Li, Y Y Liu, F Guo, Z Q Chen, H L Liu, X Q Gao, J J Fu, G Y Yu, X Z Wang, J P Wang, Y P Zhang, F P Ji. [Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2021 Nov; 29(11):1046-1052. doi:
10.3760/cma.j.cn501113-20201010-00548. [PMID: 34933421] - Chung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, Yi-Wen Chiu, Ming-Lung Yu. Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
Journal of hepatology.
2021 10; 75(4):1006-1007. doi:
10.1016/j.jhep.2021.05.016. [PMID: 34051333] - Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Clinical and molecular hepatology.
2021 10; 27(4):575-588. doi:
10.3350/cmh.2021.0155. [PMID: 34255961] - Ruoyang Chen, Dawei Li, Ming Zhang, Xiaodong Yuan. Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.
Annals of transplantation.
2021 Sep; 26(?):e933313. doi:
10.12659/aot.933313. [PMID: 34489392] - Babak Sayad, Reza Khodarahmi, Farid Najafi, Ronak Miladi, Zeinab Mohseni Afshar, Feizollah Mansouri, Zohreh Rahimi, Maria Shirvani, Mehdi Salimi, Siavash Vaziri, Alireza Janbakhsh, Fatemeh Khosravi Shadmani, Arezoo Bozorgomid, Mohammad Hossein Zamanian, Mandana Afsharian. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
The Journal of antimicrobial chemotherapy.
2021 07; 76(8):2158-2167. doi:
10.1093/jac/dkab152. [PMID: 34037760] - Joel V Chua, Afua Ntem-Mensah, Ameer Abutaleb, Jennifer Husson, Lydiah Mutumbi, Ka Wing Lam, Alip Ghosh, Sara Romani, Bhawna Poonia, Sam Lee, M Luz Pascual, Lyn R Frumkin, Shyamsundaran Kottilil. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study.
Journal of medical virology.
2021 06; 93(6):3752-3760. doi:
10.1002/jmv.26652. [PMID: 33150966] - Norah A Terrault, James Burton, Mark Ghobrial, Elizabeth Verna, Johanna Bayer, Christina Klein, David Victor, Sumit Mohan, James Trotter, Jennifer Dodge, Claus U Niemann, Raymond A Rubin. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Hepatology (Baltimore, Md.).
2021 06; 73(6):2110-2123. doi:
10.1002/hep.31551. [PMID: 32926749] - Sunil Taneja, Ajay Duseja, Manu Mehta, Arka De, Nipun Verma, Madhumita Premkumar, Radha K Dhiman, Virendra Singh, Mini P Singh, Radha K Ratho, Raja Ramachandran, Vivek Kumar, Harbir S Kohli. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
Liver international : official journal of the International Association for the Study of the Liver.
2021 04; 41(4):705-709. doi:
10.1111/liv.14685. [PMID: 33025685] - Tzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Ping-Hsin Hsieh, Wan-Long Chuang, Ming-Lung Yu. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
The Kaohsiung journal of medical sciences.
2021 Apr; 37(4):334-345. doi:
10.1002/kjm2.12315. [PMID: 33151016] - Satoshi Takakusagi, Megumi Shimizu, Yozo Yokoyama, Kazuko Kizawa, Kyoko Marubashi, Takashi Kosone, Ken Sato, Satoru Kakizaki, Hitoshi Takagi, Toshio Uraoka. Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Clinical journal of gastroenterology.
2020 Dec; 13(6):1303-1309. doi:
10.1007/s12328-020-01229-x. [PMID: 32914297] - Sayed M Derayea, Mohamed A Abdel-Lateef, Mahmoud A Omar, Ramadan Ali. Thin-layer chromatography/fluorescence detection approach for sensitive and selective determination of hepatitis C virus antiviral (velpatasvir): application to human plasma.
Luminescence : the journal of biological and chemical luminescence.
2020 Nov; 35(7):1048-1055. doi:
10.1002/bio.3816. [PMID: 32350964] - Sabela Lens, Mireia Miquel, Beatriz Mateos-Muñoz, Javier García-Samaniego, Xavier Forns. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain.
Journal of hepatology.
2020 11; 73(5):1262-1263. doi:
10.1016/j.jhep.2020.07.007. [PMID: 32673740] - Juan Li, Dong-Bo Wu, Wei Jiang, Xue-Bin Chen, Gui-Bao Xiao, Yong-Hong Wang, Meng-Lan Wang, Ya-Chao Tao, En-Qiang Chen. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Medicine.
2020 Oct; 99(43):e22726. doi:
10.1097/md.0000000000022726. [PMID: 33120769] - J P Li, X F Chen, Q Yan, Y J Zhang, Z W Xie, Y Xia, Y J Guan. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2020 Oct; 28(10):831-837. doi:
10.3760/cma.j.cn501113-20200831-00486. [PMID: 33105927] - Babak Sayad, Mahsa Sobhani, Reza Khodarahmi. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?.
Archives of medical research.
2020 08; 51(6):577-581. doi:
10.1016/j.arcmed.2020.04.018. [PMID: 32387040] - A Izzi, V Messina, L Rinaldi, P Maggi. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
European review for medical and pharmacological sciences.
2020 05; 24(10):5193-5194. doi:
10.26355/eurrev_202005_21297. [PMID: 32495848] - Sandip K Zalawadiya, JoAnn Lindenfeld, Ashish Shah, Mark Wigger, Matthew Danter, D Marshall Brinkley, Jonathan Menachem, Lynn Punnoose, Keki Balsara, Suzanne Brown Sacks, Henry Ooi, Roman Perri, Joseph Awad, Sarah Smith, Rachel Fowler, Heather O'Dell, Callie Darragh, Shelly Ruzevich-Scholl, Kelly Schlendorf. Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
ASAIO journal (American Society for Artificial Internal Organs : 1992).
2020 05; 66(5):553-558. doi:
10.1097/mat.0000000000001034. [PMID: 31425256] - Cuiyun Li, Xiaojiao Li, Xiaoxue Zhu, Hong Zhang, Gong Shen, Kathryn Kersey, Yanhua Ding. Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Clinical therapeutics.
2020 03; 42(3):448-457. doi:
10.1016/j.clinthera.2020.01.013. [PMID: 32115243] - Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.
F1000Research.
2020; 9(?):129. doi:
10.12688/f1000research.22457.2. [PMID: 32194944] - Minou van Seyen, Angela Colbers, Evertine J Abbink, Joost P H Drenth, David M Burger. Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers.
Clinical pharmacology and therapeutics.
2019 11; 106(5):1093-1098. doi:
10.1002/cpt.1569. [PMID: 31313296] - Sergio M Borgia, Janet Dearden, Eric M Yoshida, Stephen D Shafran, Ashley Brown, Ziv Ben-Ari, Matthew E Cramp, Curtis Cooper, Matthew Foxton, Conrado Fernandez Rodriguez, Rafael Esteban, Robert Hyland, Sophia Lu, Brian J Kirby, Amy Meng, Svetlana Markova, Hadas Dvory-Sobol, Anu O Osinusi, Rafael Bruck, Javier Ampuero, Stephen D Ryder, Kosh Agarwal, Raymond Fox, David Shaw, Shariq Haider, Bernard Willems, Yoav Lurie, Jose Luis Calleja, Edward J Gane. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Journal of hepatology.
2019 10; 71(4):660-665. doi:
10.1016/j.jhep.2019.05.028. [PMID: 31195062] - Yasir Mehmood, Ikram Ullah Khan, Yasser Shahzad, Syed Haroon Khalid, Muhammad Irfan, Sajid Asghar, Abid Mehmood Yousaf, Talib Hussain, Ikrima Khalid. Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma.
Pakistan journal of pharmaceutical sciences.
2019 Jul; 32(4(Supplementary)):1835-1842. doi:
NULL. [PMID: 31680080] - Michael Duerr, Eva V Schrezenmeier, Lukas J Lehner, Léon Bergfeld, Petra Glander, Stephan R Marticorena Garcia, Christian E Althoff, Ingolf Sack, Susanne Brakemeier, Kai-Uwe Eckardt, Klemens Budde, Fabian Halleck. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
BMC nephrology.
2019 02; 20(1):36. doi:
10.1186/s12882-019-1218-0. [PMID: 30717681] - Josip Begovac, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob, Šime Zekan. Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir: A case report.
Medicine.
2018 Dec; 97(51):e13671. doi:
10.1097/md.0000000000013671. [PMID: 30572487] - Mamdouh R Rezk, Emad B Basalious, Kamal A Badr. Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS method: Application to a bioequivalence study.
Biomedical chromatography : BMC.
2018 Nov; 32(11):e4347. doi:
10.1002/bmc.4347. [PMID: 30047564] - Mahmoud A Omar, Mohamed A Abdel-Lateef, Ramadan Ali, Sayed M Derayea. Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma.
Luminescence : the journal of biological and chemical luminescence.
2018 Nov; 33(7):1249-1256. doi:
10.1002/bio.3542. [PMID: 30144265] - Erik Mogalian, Diana M Brainard, Anu Osinusi, Lisa Moorehead, Bernard Murray, Kah Hiing John Ling, Robert Perry, Craig Curtis, Eric Lawitz, Kenneth Lasseter, Thomas Marbury, Anita Mathias. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Clinical pharmacokinetics.
2018 11; 57(11):1449-1457. doi:
10.1007/s40262-018-0645-6. [PMID: 29520729] - Brian L Pearlman, Andrew E Hinds. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Alimentary pharmacology & therapeutics.
2018 11; 48(9):914-923. doi:
10.1111/apt.14977. [PMID: 30288771] - Erik Mogalian, Luisa M Stamm, Anu Osinusi, Diana M Brainard, Gong Shen, Kah Hiing John Ling, Anita Mathias. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2018 08; 67(6):934-940. doi:
10.1093/cid/ciy201. [PMID: 29522076] - E Lawitz, B Freilich, J Link, P German, H Mo, L Han, D M Brainard, J McNally, T Marbury, M Rodriguez-Torres. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Journal of viral hepatitis.
2015 Dec; 22(12):1011-9. doi:
10.1111/jvh.12435. [PMID: 26183611] - Paul Targett-Adams, Emily J S Graham, Jenny Middleton, Amy Palmer, Stephen M Shaw, Helen Lavender, Philip Brain, Thien Duc Tran, Lyn H Jones, Florian Wakenhut, Blanda Stammen, David Pryde, Chris Pickford, Mike Westby. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
Journal of virology.
2011 Jul; 85(13):6353-68. doi:
10.1128/jvi.00215-11. [PMID: 21507963]